CN205459229U - Drug coating metal air flue support - Google Patents
Drug coating metal air flue support Download PDFInfo
- Publication number
- CN205459229U CN205459229U CN201620071612.4U CN201620071612U CN205459229U CN 205459229 U CN205459229 U CN 205459229U CN 201620071612 U CN201620071612 U CN 201620071612U CN 205459229 U CN205459229 U CN 205459229U
- Authority
- CN
- China
- Prior art keywords
- air flue
- model
- utility
- metal air
- medication coat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The utility model relates to a drug coating metal air flue support, including metal air flue support body, metal air flue support body is woven by the wire material and is formed its characterized in that: the surface of wire material is provided with and is used for restraining the hyperplastic drug coating of granulation tissue. The utility model discloses be provided with on the surface of metal air flue support and be used for restraining the hyperplastic drug coating of granulation tissue, consequently can restrain the granulation tissue hyperplasia effectively after putting into the air flue to avoid causing the official jargon restenosis.
Description
Technical field
This utility model relates to a kind of medication coat metal airway stent, belongs to medical instruments field.
Background technology
Support is for treating the history in airway constriction existing more than 20 years, but during inserting, tunica mucosa tracheae can be caused by support
Damage, additionally, support itself stimulates as foreign body may result in granulation tissue hyperplasia, causes tube chamber restenosis, serious shadow
Ring the clinical efficacy after inserting.Topical application anti-proliferative drugs can suppress granulation tissue hyperplasia, but drug treating time
Short, it is impossible to suppress narrow happening over and over again.
Summary of the invention
For the problems referred to above, the purpose of this utility model is to provide one can suppress air flue granulation tissue hyperplasia and suppression
The medication coat metal airway stent of persistent.
For achieving the above object, this utility model by the following technical solutions: a kind of medication coat metal airway stent,
Including metal airway stent body, described metal airway stent body is formed by metal wire material braiding, it is characterised in that:
Surface configuration at described metal wire material has the medication coat for suppressing granulation tissue hyperplasia.
Described metal airway stent body is soaked in coating solution after drying again and is formed by described medication coat.
Described coating solution is dissolved in dichloromethane by the paclitaxel of 0.1%W/V and the Poly(D,L-lactide-co-glycolide of 2%W/V
Alkane is formulated.
This utility model is owing to taking above technical scheme, and it has the advantage that 1, this utility model is at metal air flue
The surface configuration of support has the medication coat for suppressing granulation tissue hyperplasia, therefore can be effectively after inserting air flue
Suppression granulation tissue hyperplasia, thus avoid causing official jargon restenosis.2, this utility model medication coat uses paclitaxel to make
For slow releasing agent, after being coated in metal support surface, release time can be up to 5 months as long as, therefore, to granulation tissue
The inhibitory action of hypertrophy is lasting.
Accompanying drawing explanation
Fig. 1 is overall structure schematic diagram of the present utility model；
Fig. 2 is the relation schematic diagram of this utility model metal wire material and medication coat.
Detailed description of the invention
With embodiment, this utility model is described in detail below in conjunction with the accompanying drawings.
As shown in Figure 1 and Figure 2, the utility model proposes a kind of medication coat metal airway stent, it includes metal
Airway stent body 1, metal airway stent body 1 is formed, in the surface configuration of metal wire material by metal wire material braiding
There is the medication coat 2 for suppressing granulation tissue hyperplasia.
Further, this utility model airway stent is to be immersed in by metal airway stent body 1 in coating solution 1 day
Rear taking-up is dried and is obtained.The coating solution paclitaxel by 0.1%W/V and the poly lactic-co-glycolic acid copolymerization of 2%W/V
It is formulated that thing is dissolved in dichloromethane.
The beneficial effects of the utility model are as follows:
Use the configuration of surface of scanning electron microscopic observation this utility model support, surveyed by high performance liquid chromatography (HPLC)
Its drug loading fixed.This utility model support prepared is put into persistent oscillation in PBS solution, assesses its release in vitro
Kinetics.Being the support of 16.3806 ± 0.0021mg for drug loading, release in vitro result display paclitaxel can be slow
Sustained release more than 40 days, the paclitaxel of release was about 0.3763 ± 0.0038mg, all at effective dose model every day
In enclosing, it is possible to realize medicine and slowly discharge and can effectively suppress cicatrix granulation tissue to be formed.
After animal contrast experiment verifies that discovery, this utility model support are inserted in animal body, do not find relevant concurrent
Disease.Compared with the metal rack being not provided with medication coat, the granulation tissue hyperplasia degree of Paclitaxel eluting stent substantially subtracts
Gently, and rack surface realizes endothelialization and has normal tracheal cilia to cover.Paclitaxel eluting stent surface drug is being put
Discharging the fastest in entering latter 1 month, release is up to 70.85%, and hereafter release slows down gradually, to the completeest when 5 months
Full release, release reaches 98.46%.As can be seen here, Paclitaxel eluting stent is inserted after in animal body can realize slow release,
In the tracheal tissue that support covers, the tracheal tissue of a frame peripheral and lung tissue, Ramulus et folium taxi cuspidatae is all can detect that in observing time
Alcohol composition, concentration is within safety range；But extending with standing time, in each tissue, drug level gradually lowers.Combine
On, Paclitaxel eluting stent can effectively suppress support to insert the propagation of rear granulation tissue, reduces the formation of restenosis,
And drug level is safe.
The various embodiments described above are merely to illustrate this utility model, and the structure of the most each parts, connected mode etc. are all permissible
It is varied from, every equivalents carried out on the basis of technical solutions of the utility model and improvement, the most should not arrange
In addition at protection domain of the present utility model.
Claims (3)
1. a medication coat metal airway stent, including metal airway stent body, described metal airway stent body
Formed by metal wire material braiding, it is characterised in that: the surface configuration at described metal wire material has for suppressing granulation tissue
The medication coat of hypertrophy.
2. a kind of medication coat metal airway stent as claimed in claim 1, it is characterised in that: described medication coat
Described metal airway stent body is soaked in coating solution and is formed after drying again.
3. a kind of medication coat metal airway stent as claimed in claim 2, it is characterised in that: described coating solution
It is dissolved in dichloromethane formulated by the paclitaxel of 0.1%W/V and the Poly(D,L-lactide-co-glycolide of 2%W/V.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201620071612.4U CN205459229U (en) | 2016-01-25 | 2016-01-25 | Drug coating metal air flue support |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201620071612.4U CN205459229U (en) | 2016-01-25 | 2016-01-25 | Drug coating metal air flue support |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN205459229U true CN205459229U (en) | 2016-08-17 |
Family
ID=56639597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201620071612.4U Expired - Fee Related CN205459229U (en) | 2016-01-25 | 2016-01-25 | Drug coating metal air flue support |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN205459229U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107899093A (en) * | 2017-12-05 | 2018-04-13 | 韩新巍 | It is a kind of to be used to suppress inner airway stent of air flue inner membrance granulation tissue hyperplasia and preparation method thereof |
-
2016
- 2016-01-25 CN CN201620071612.4U patent/CN205459229U/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107899093A (en) * | 2017-12-05 | 2018-04-13 | 韩新巍 | It is a kind of to be used to suppress inner airway stent of air flue inner membrance granulation tissue hyperplasia and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8518429B2 (en) | Arsenic trioxide medical elution scaffold | |
| Bhat et al. | The mTOR pathway in hepatic malignancies | |
| AU735655B2 (en) | Compositions and methods for treating or preventing inflammatory diseases | |
| US11167066B2 (en) | Local drug delivery devices and methods for treating cancer | |
| JP2714415B2 (en) | Formulation for therapeutic agent administration | |
| Hernandez et al. | Effect of tissue microenvironment on fibrous capsule formation to biomaterial-coated implants | |
| Lee et al. | Acceleration of re-endothelialization and inhibition of neointimal formation using hybrid biodegradable nanofibrous rosuvastatin-loaded stents | |
| AU2013318146B2 (en) | Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium | |
| US20080245375A1 (en) | Benign Prostatic Hyperplasia Treatments | |
| JP2009523133A (en) | Nanoparticle-containing drug compounds useful for the treatment of restenosis lesions | |
| JP2004521918A (en) | Pharmaceutical preparations | |
| Chung et al. | Inflammation‐induced drug release by using a pH‐responsive gas‐generating hollow‐microsphere system for the treatment of osteomyelitis | |
| Cheng et al. | In vivo inhibition of hypertrophic scars by implantable ginsenoside-Rg3-loaded electrospun fibrous membranes | |
| JP2011519967A5 (en) | ||
| Díaz-Herráez et al. | Adipose-derived stem cells combined with neuregulin-1 delivery systems for heart tissue engineering | |
| US9028847B2 (en) | Sodium alginate crosslinked slow-release moxifloxacin microsphere, the preparation method and the use thereof, and target vascular occlusive agent of the microsphere | |
| CN103990221A (en) | Medicine elution balloon device | |
| Abasalta et al. | Adsorption and sustained release of doxorubicin from N-carboxymethyl chitosan/polyvinyl alcohol/poly (ε-caprolactone) composite and core-shell nanofibers | |
| JP2016526039A5 (en) | ||
| JP2007504273A (en) | Pharmaceutical composition and method for inhibiting fibrous adhesion using various agents | |
| CN205459229U (en) | Drug coating metal air flue support | |
| Mao et al. | Novel alginate–chitosan composite microspheres for implant delivery of vancomycin and in vivo evaluation | |
| Hussain et al. | Nanofibrous drug delivery systems for breast cancer: a review | |
| JP5599585B2 (en) | Compositions containing silver nanoparticles and pulverulent extract and uses thereof | |
| US20160008313A1 (en) | Compositions for anti-inflammatory, antioxidant effects and improved respiratory function by specific histone deacetylase inhibition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160817 Termination date: 20220125 |